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Ankrd2 is a member of the Muscle Ankyrin Repeat Protein family (MARPs), consisting of sarcomere-associated proteins that can also localize in
the nucleus. There are indications that MARPs might function as shuttle proteins between the cytoplasm and nucleus, likely sending information to
the nucleus concerning the changes in the structure or function of the contractile machinery. Even though recent findings suggest that theMARP gene
family is not essential for the basal functioning of skeletal muscle, its influence on the gene expression program of skeletal muscle cells was
highlighted. To investigate this regulatory role we produced and examined both morphological and functional features of myocytes stable
overexpressing or silencing the Ankrd2 protein. The transcriptional profiles of the myocytes revealed that the molecular pathways perturbed by
changes in Ankrd2 protein level are congruent with the morpho-physiological and biochemical data obtained in Ankrd2-modified myoblasts induced
to differentiate. Our results suggest that Ankrd2 gives an important contribution to the coordination of proliferation and apoptosis during myogenic
differentiation in vitro, mainly through the p53 network.
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Skeletal muscle tissue possesses an elevated plasticity to
adapt to a variety of stimuli (exercise, denervation, starvation or
hypoxia) [1] as well as regeneration capacity since it is frequently
exposed to damage (degenerative pathologies, direct trauma,
invasive surgery, etc.). The muscle remodelling involves mainly
a) nuclear reprogramming related to the adaptations in the myo-
sin type, protein turnover, and the cytoplasm-to-myonucleus
ratio and b) activation, proliferation and fusion of satellite cells, a
population of stem cells that exist beneath the basal lamina that
surrounds eachmyofibre [2]. Recently, gene expression profiling⁎ Corresponding author. Tel.: +39 0498276221; fax: +39 0498276280.
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doi:10.1016/j.bbamcr.2008.01.027analysis has demonstrated that transcriptional adaptations in
skeletal muscle involve a broad range of genes and that mRNA
changes often run parallel for genes in the same functional
categories [3–5]. Several signalling pathways involving cyto-
plasmic protein kinases and nuclear-encoded transcription
factors are recognized as potential master regulators that trans-
duce physiological stress into transcriptional adaptations of bat-
teries of metabolic and contractile genes [6]. Moreover, many
cytoskeleton-associated proteins displaying dynamic distribu-
tions within cells are mechanically sensitive and are excellent
candidates for involvement in the adaptive response to mecha-
nical perturbation [7]. Currently, several sarcomere-associated
proteins have been reported to reside in the nucleus, where they
could participate in the response of the cell to changes in the
structure or function of the contractile machinery [8,9]. The
MARP family, or muscle ankyrin repeat proteins, (cardiac anky-
rin repeat protein CARP, Ankrd2/Arpp, and diabetes-associated
ankyrin repeat protein DARP), have been shown in vivo and
in vitro to be highly responsive to muscle mechanical status
[10,11]. There are many studies that show that Ankrd2 is highly
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nantly in type I skeletal muscle fibres [12]. Interestingly, dener-
vation of slow muscle (soleus) decreases the level of Ankrd2 to
below the detection limit in 4 weeks [13], whereas denervation of
fast muscle (gastrocnemius) increases its expression [12]. The
level of Ankrd2 mRNA also increases after eccentric contraction
as it is sensitive to the mode of contraction (eccentric vs. iso-
metric), but not to stress [14,15]. Ankrd2 mRNA level increases
in diabetic muscle, a likely consequence of transition towards a
slower fibre type, which is decreased by exercise [4]. TheMARP
family proteins can form a complex with titin, myopalladin and
calpain protease p94 and would appear to be involved in sig-
nalling and regulation of gene expression [11]. It was recently
shown that Ankrd2/Arpp can also interact with three transcrip-
tion factors: YB1, PML and p53 as well as with the Z-disc
protein telethonin [16]. Interestingly, Ankrd2/Arpp not only
binds p53 but also modulates its activity, supporting the idea that
Ankrd2/Arpp may be involved in sensing stress signals and
linking these to muscle gene regulation [16]. The role of Ankrd2
in the modulation of p53 transcriptional activity and its inter-
action with YB-1, which through the interaction with CARP
participates in the regulation of gene expression during heart
development [17] suggest that Ankrd2 could take part in myo-
genesis. This hypothesis is supported by the observation that
Ankrd2 is strongly expressed upon differentiation of skeletal
muscle cells [18]. Recently we also demonstrated its regulation
by the muscle-specific transcription factor MyoD [19]. However
the precise role that Ankrd2 plays remains unclear, complicated
by the finding that Ankrd2-knock-out mice did not show a
defined impaired muscular phenotype [20].
The aim of our work was to study the possible role of Ankrd2
as a myogenic regulator. To explore the function of Ankrd2 we
carried out both overexpression and antisense experiments in
the myogenic cell line C2C12 that provides a good model for
the major steps of muscle differentiation. A survey of morpho-
logical and functional characteristics of transfected cells was
performed during many stages of differentiation. We show that
the overexpression of Ankrd2 in proliferating myoblasts se-
riously compromises the differentiation program activating the
p53-dependent cell death pathway [21]. Here we present the
first evidence of how Ankrd2 might influence muscle differ-
entiation by modulating p53-transcriptional activity. We have
also used global transcriptome analysis which allows simulta-
neous investigation of interacting pathways. The microarray
results corroborate the morphological and biochemical data
showing clear evidences of a role for Ankrd2 in the processes
that coordinate proliferation and differentiation in muscle.
2. Materials and methods
2.1. Mammalian cell culture
C2C12 mouse cell line was cultured as previously described [19].
2.2. Cloning of Ankrd2 transcript in sense and antisense orientation
The 1102 bp murine Ankrd2 cDNAwas obtained by reverse transcription of
2 μg of total RNA extracted from C2C12 myotubes in 20 μl reaction using theSuperscript II kit (Invitrogen) followed by a PCR step using 1/20 of theRT-reaction
and two pairs of Ankrd2 specific primers designed to perform the directional
cloning of Ankrd2 cDNA in sense and antisense orientations (Ankrd2 sense:
5′-CCGGAATTCATGGAGGGTACCATGGAGGGG-3′ and 5′-AACCCGGC-
TCGAGCGGCCGCGAGCAAAGCCAGCACTTTATTG-3′; Ankrd2 antisense:
5′-AACCCGGCTCGAGCGGCCGCATGGAGGGTACCATGGAGGG-3′
and 5′-CCGGAATTCAGCAAAGCCAGCACTTTATTG-3′). High fidelity PCR
was performedwith Pfu Turbo polymerase (Stratagene). After purification, the PCR
fragments were EcoRI/NotI digested, directionally ligated to the pcDNA3.0
mammalian expression vector (Invitrogen) and cloned intoDH10BEscherichia coli
strain. The bacterial clones were checked for insert integrity by direct sequencing.
2.3. Transfection and selection of stably transformed myoblast clones
The mammalian expression plasmids pcDNA3.0 containing respectively the
Ankrd2 mouse transcript in sense and antisense orientation were independently
transfected in C2C12 cells as previously described [19]. For each transfection
about 48 G418-resistant clones were selected and screened to identify those
functionally upregulating and silencing Ankrd2 expression. The correct inte-
gration of inserts and the alteration of Ankrd2 both at mRNA and protein level
were verified as previously described [19]. The sequences of Ankrd2-specific
primers used in real-time quantitative PCR are 5′-CGTGAGACTCAACCGC-
TACA-3′ and 5′-GCAGGCAGCTCATAGTAGGG-3′. Values were normalized
to the expression of the B2m internal reference (see par. 2.5). In a Western blot
experiment we used N-terminal Ankrd2-specific antibody [18] testing in parallel
the constitutive level of Hdac1 protein (Santa Cruz) as reference.
2.4. Morphological characterization and fusion index assessment
Both stable transfected and control myoblasts were seeded at a density of
1×105 cells per 35 mm plate. After 1, 3 and 6 days of incubation in differen-
tiation medium, cultures were fixed with 4% PFA and immunostained for sarco-
meric α-actinin (1:250 dilution; Sigma). Secondary TRITC-conjugated rabbit
anti-mouse antibody (Dako) was used at 1/100 dilution. For fusion index assays,
the same slides were used. For each sample, 10 fields were randomly chosen for
counting. Fusion index was defined as the number of nuclei within α-actinin
stained myotubes containing over 3 nuclei, among 100 DAPI stained nuclei
counted in the same field. Each experiment was repeated to validate the results.
2.5. Real-time PCR
Real-time quantitative PCR (RQ-PCR) based on the SYBR Green chemistry
(Finnzymes) was carried out as described in a previous study [19]. Primer
sequences were designed to amplify the following mouse transcripts: MyoD
(5′-CTCTGATGGCATGATGGATT-3′ and 5′-GTGGAGATGCGCTCCAC-
TAT-3′), Myf-5 (5′-ACGGCATGCCTGAATGTAAC-3′ and 5′-AAGCAATC-
CAAGCTGGACAC-3′), Myogenin (5′-CCAACCCAGGAGATCATTTG-3′
and 5′-ACCCAGCCTGACAGACAATC-3′), Myh1 (5′-ACCTTGTGGACAA-
ACTGCAA-3′ and 5′-AGCTTGTTGACCTGGGACTC-3′), p53 (5′-GTACC-
TTATGAGCCACCCGA-3′ and 5′-CTTCTGTACGGCGGTCTCTC-3′), Cdkn1a
(5′-TTGCACTCTGGTGTCTGAGC-3′ and 5′-CTCCTGACCCACAGCAGA-
AG-3′), Gadd45a (5′-GAAGACCGAAAGGATGGACA-3′ and 5′-GCAGG-
CACAGTACCACGTTA-3′), Bax (5′-CGAGCTGATCAGAACCATCA-3′ and
5′-CTCAGCCCATCTTCTTCCAG-3′) and beta-2-microglobulin (B2m) (5′-CC-
GTCTACTGGGATCGAGAC-3′ and 5′-GCTATTTCTTTCTGCGTGCAT-3′).
Differences in gene expression between the sample (Ankrd2-clones) and control
(C2C12) were evaluated by a relative quantification method [22]. Values were
normalized to the expression of the B2m internal reference, whose abundance did
not change under our experimental conditions. Standard deviations were calcu-
lated according to the mathematical methodologies described by Marino and
collaborators [23].
2.6. Flow cytometric analysis of cell cycle
Ankrd2-overexpressing and -silencing clones and C2C12 control cells were
plated at the same cellular density, grown for 2 days and then harvested. For each
sample, 1×106 cells were fixed with 70% cold (–20 °C) ethanol, washed with
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for 60 min at 37 °C. Samples were analyzed by BD FACScan (Becton Dickin-
son). The analysis was repeated with 2 independent samples for each cell clones.
2.7. Western blot
Equal amounts of whole cell lysates extracted from Ankrd2-overexpressing
and -silencing myoblasts and control cells were separated on 4%–12% Bis–Tris
NuPAGE Pre-Cast Gels (Invitrogen). Proteins were transferred to Hybond-C
Extra membrane (Amersham) and stained with Ponceau S solution to verify
transfer. Then the blots were incubated in blocking buffer [1× Phospate-buffered
saline (PBS), 0.05% Tween 20, 10% non fat milk] for 3 h at room temperature.
Membranes were washed in washing buffer (1× PBS, 0.05% Tween 20) three
times, 10 min each, and probed with the primary antibody and then the sec-
ondary antibody respectively for 2 and 1 h in 1× PBS, 0.05% Tween 20, and 2%
non fat milk. Primary antibodies were anti-p21, anti-p53 and as loading control
anti-Hdac1 (Santa Cruz). Equal amounts of whole cell lysates from transfected
and control myoblasts at 6 days of differentiation were separated on 3–8% Tris–
Acetate NuPAGE Pre-Cast Gels (Invitrogen). The expression level of myosin
protein was revealed by incubation of the transferred proteins with both anti
sarcomeric myosin heavy chain MF 20 antibody (Developmental Studies Hy-
bridoma bank) and anti Myosin Skeletal Slow antibody (Sigma), testing in
parallel the constitutive level of beta-actin protein (Sigma) as reference.
2.8. Cell proliferation assay
BrdU assays on stably transfected and control C2C12 cells were performed
as previously described [19]. Briefly, different culture stages were incubated
with BrdU for 4 h and immunostained with a mouse anti-BrdU monoclonal
antibody. For each clone the mean percentage number of BrdU-positive nuclei
from a total number of DAPI-labelled nuclei counted in 10 fields was calculated.
Each experiment was repeated to validate the results.
2.9. Apoptosis assay
Transfected clones and control cells were seeded at a density of 1×105 cells in
35 mm diameter plates. After 1 day of incubation in differentiation medium, the
reagent solution able to bind covalently to the active caspases was added to each
sample, according to the instructions of CaspaTag Pan-Caspase In Situ assay Kit
(CHEMICON). Next, the cells were fixed and observed under a Leica5000
DFC300FX microscope to view the red fluorescence of caspase positive-cells.
For each sample the mean of the caspase positive-cells normalized on the total
DAPI-labelled cells in 10 microscope fields was assessed. Each experiment was
repeated to validate the results.
2.10. Caspase-3 activity assay
Caspase-3 activity was determined by measuring the absorbance at 405 nm of
the chromophore p-nitroaniline (pNA) after cleavage from the labelled substrateFig. 1. Subcellular localization of Ankrd2 protein in C2C12 myoblasts and
myotubes; Ankrd2 mRNA and protein expression levels in C2C12 transfected
clones. A. In panel I cells were immunostained only with secondary TRITC-
conjugated antibody. Cells were treated with antibody specific for the N-terminal
of Ankrd2 [18] to localize the protein in the myogenic cell line (red). Ankrd2
localizes in the nucleus of proliferating myoblasts (panel II and III) and moves to
the cytoplasm of differentiated myotubes (panels from IV to VI). B. Ankrd2-
expression level alterations were quantified by real-time-PCR. The level of
Ankrd2 mRNA for each transfected clone is expressed as fold increase relative to
control cells. The means±SE of triplicate determinations for each clones are
shown. Statistical analysis was carried out (each bar n=3); ⁎P, b0.05%. C. West-
ern blot with antibody to N-terminal Ankrd2 using protein extracts from C2C12
untransfected control cells (C1), two clones transfected with empty vectors (C2
and C3) and Ankrd2-sense (+) and antisense (−) transfected clones. Hdac1 is the
loading control. The most effective Ankrd2 overexpression was obtained in the
Ankrd2(+)cl.S9 and the most effective silencing in Ankrd2(−)cl.A9.DEVD-pNA. The experiments were performed according to the protocol supplied
by Caspase-3 Colorimetric Activity Assay Kit (CHEMICON). Briefly, cells were
collected at different culture stages by scraping them in ice-cold phosphate-buffered
saline, centrifuged and lysed on ice for 10min in the lysis buffer provided in the kit.
The assay mixtures prepared according to the manufacturer's instructions were
incubated overnight at 37 °C. The samples were read at 405 nm in the microtiter
plate reader Biotrack II. Each experiment was repeated to validate the results.
2.11. Cell viability assay
Stable C2C12 clones and control cells at different culture stages were
assayed for their ability to convert soluble MTT into insoluble purple formazan.
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was used following the manufacturer's instructions. Briefly, for each sample
during the last 4 h of incubation the media was replaced by MTT solution. Then,
the absorbance at 490 nm was recorded using the microtiter plate reader Biotrack
II. Each experiment was repeated to validate the results.
2.12. Transcriptome analysis
Gene expression profiling experiments were performed using a mouse mic-
roarray platform containing a collection of 13,443 70mer oligonucleotide probes
(Qiagen-Operon, version 1.1). The architecture of the mouse platform has been
deposited in the GEO Database (Accession Number GPL5098). Total RNAwas
purified from C2C12 Ankrd2-overexpressing and -silencing clones and from
C2C12 control cells at proliferatingmyoblast stage, following the standard Trizol
protocol. The RNA 6000 LabChip kit (Agilent Technologies) was used for RNA
quantification and quality control in conjunction with an Agilent Bioanalyzer
2001. Preparation of microarray platforms, RNA labelling, hybridization and
detection of differentially expressed transcripts have been performed as pre-
viously described [24]. Normalization of the expression levels was performed
with the MIDAW tool (http://midaw.cribi.unipd.it/dnachip/) [25]. The log2 ex-
pression ratios calculated by MIDAW on each array probe of each competitive
hybridization experiment were processed for consistency by the Statistical Ana-
lysis of Microarrays software (SAM, http://www-stat.stanford.edu/~tibs/SAM/).
On the basis of the SAM output, the threshold level for False Discovery Rate was
setb1%. Microarray raw and normalized data are available at GEO Database
using the GEO Series accession number GSE7542.
3. Results
3.1. Ankrd2 localizes in the nucleus of C2C12 proliferating
myoblasts
We have used an antibody to the N-terminal of Ankrd2 [18] to
localize the protein in both proliferating and differentiating
C2C12 myoblast cell cultures. These immunofluorescence ex-
periments confirmed our previous finding on the nuclear loca-
lization of the Ankrd2 protein in proliferating human myoblasts
[18]. Upon induction ofmyogenic differentiation, Ankrd2moves
to the cytoplasm of C2C12multinucleated myotubes. The panels
in Fig. 1A show these multiple subcellular localizations in pro-
liferating C2C12 cells and C2C12myoblasts grown in myogenic
differentiation medium. On the basis of these results, we hypo-
thesized that Ankrd2 could have a role in the regulation of the
differentiation process. Moreover, the published data showing
the temporal and spatial related expression of the Ankrd2 gene
during myogenic differentiation stages corroborate our insight.
3.2. Construction of Ankrd2-overexpressing and Ankrd2-silencing
C2C12 clones
To study the role of the muscle-specific Ankrd2 gene in
myogenic differentiation we generated constructs designed toFig. 2. Impairment of myogenic differentiation in Ankrd2-overexpressing and -silen
anti-α-actinin-2 antibody (red). Nuclei were visualized by DAPI (blue). Incubation o
a1, a2, a3) resulted in a rapid increase in α-actinin synthesis and formation of elongate
form multinucleated elongated myotubes (panels b and c) while Ankrd2-silencing cel
taken with 40× objective, panels 2 and 3 with 20×. B. Calculation of fusion indexes
confirmed that Ankrd2-overexpressing and -silencing myoblasts were deficient in fus
profile of the muscle differentiation regulators (MRFs) MyoD, Myogenin and Myf-5
gene was used as reference gene. The values are expressed as percentage relative to th
differentiation failure of Ankrd2-overexpressing clones and with the reduced myotueither constitutively express high levels of recombinant Ankrd2
protein or to silence the endogenous Ankrd2 protein in myo-
blasts. The Ankrd2 transcript was cloned in pcDNA 3.0mamma-
lian expression vectors both in sense and antisense orientation.
Each construct was independently transfected into C2C12 cells.
Cells were selected for ten days and 48 G418-resistant clones
were tested for Ankrd2 overexpression or silencing. First how-
ever, the correct integration of each construct in the genomic
DNAwas verified by PCR and subsequently the overexpression
and silencingwere tested by real-time-PCR andWestern blotting.
Two sense (Ankrd2(+)cl.S9 and Ankrd2(+)cl.S12) and two
antisense Ankrd2 clones (Ankrd2(−)cl.A9 and Ankrd2(−)cl.
A10) that gave positive results in the tests described above were
finally selected and studied by comparison with C2C12 control
cells. To avoid the bias of clone selectionwe used two clones both
for overexpression and silencing studies. As shown in Fig. 1B
and C, the most effective Ankrd2-overexpression was seen with
the Ankrd2(+)cl.S9 and the most effective silencing with Ankrd2
(−)cl.A9. The transcript and protein levels of Ankrd2 in the
different clones were compared with that of two clones stably
transfected with empty vectors as well as the untransfected
C2C12 cell line, since the empty vector integration event into the
genome might per se alter the normal phenotype. Nevertheless,
we have verified by microarray experiment that there are no
significant differences in the transcriptional profile between
untransfected and empty-plasmid transfected C2C12 cells (data
not shown). Then we have used C2C12 untransfected cells as
control in the experiment discussed afterwards.
3.3. The upregulation of Ankrd2 protein level seriously impairs
myogenic differentiation potential
To examine the role of Ankrd2 in myogenic differentiation we
analyzed the crucial events of this process: cell cycle exit upon
induction of myogenic differentiation, acquisition of an apopto-
sis-resistance phenotype, cell viability and fusion of myoblasts
into multinucleated myotubes.
First, we studied the morphological features of the clones
induced to differentiate. When confluent cell cultures were in-
cubated in DMEM containing 2% horse serum, C2C12 control
cells acquired elongated morphology and fused to become mul-
tinucleated myotubes. Since the morphological conversion of
myoblasts into myotubes is accompanied by the accumulation of
muscle-specific proteinswe used an antibody formuscle-specific
alpha-actinin-2 in order to estimate the relative myogenic differ-
entiation potential in the Ankrd2-overexpressing and -silencing
clones. Fig. 2A shows the control C2C12 cells and the trans-
fected clones immunostained with the alpha-actinin-2 antibodycing clones. A. Differentiated myocytes were detected by immunostaining with
f control myoblast cultures in differentiation medium for 1, 3 and 6 days (panels
d multinucleated myotubes. By contrast, Ankrd2-overexpressing clones failed to
ls show a weaker reduction of myotube formation (panels d and e). Panels 1 were
as percent cells containing three or more nuclei within a differentiated myocyte
ion capacity. The error bars represent the 95% confident intervals. C. Expression
and of the myogenic differentiation marker Myh1. In each experiment the B2m
e correspondent control, ⁎t test, Pb0.05%. The results are in agreement with the
be formation in Ankrd2-silenced cells.
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nuclei by DAPI staining provided information about the position
of each cell with respect to adjacent cells. We show that Ankrd2overexpression is associated with reduced myotube formation
and this effect is related to the level of overexpression (Fig. 2A:
panels b and c). Instead, Ankrd2-silencing seems to cause only a
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trols, which becomes even weaker for the clone where Ankrd2 is
more effectively silenced (Fig. 2A: panels d). This result is in
agreement with the data showing that Ankrd2-knock-outmice do
not show abnormal muscle differentiation phenotypes [20]. The
fusion index of the transfected clones reflects the morphological
data (Fig. 2B). The fusion index was estimated after 3 and 6 days
from induction of differentiation as the percentage of nuclei
included into alpha-actinin-2-positive myotubes relative to 100
nuclei in the same field. The bars in Fig. 2B represent the average
number of nuclei contained in myotubes normalized to the total
number of 100 nuclei and counted in 10 microscopic fields
randomly chosen for each C2C12 cell culture. As can be seen,
Ankrd2 overexpression impairs cell fusion, proportionally with
its overexpression level. On the other hand, the more efficiently
silenced clone (A9) appears to show the same level of cell fusion
as the control cells, while the weaker Ankrd2-minus clone (A10)
is characterized by a minimally reduced fusion index.
The changes in the myogenic potential of the transfected
clones were further investigated by analyzing with real-time-
PCR the expression profiles of the myogenic differentiation
marker Myh1 and of the myogenic regulatory factors MyoD,
Myf-5 and Myogenin. As indicated in Fig. 2C, the Ankrd2-
overexpressing clones (with impaired fusion capacity) show
both a downregulation of MyoD, Myogenin and Myh1 and
upregulation of Myf-5. It is known that the Myf-5 transcript is
absent in differentiating myoblast cells (G1 exit) that express
high levels of MyoD and Myogenin, whereas it is present in
myoblasts which do not differentiate but instead exit the cell
cycle into quiescence (G0) and contain neither MyoD nor Myo-
genin [26]. These data joined with the result showing a dramatic
downregulation of Myh1 expression in the Ankrd2-overexpres-
sing clones support the impairment of the myogenic differentia-
tion process that results from the morphological analyses of the
transfected C2C12 clones. On the other hand, the study of the
expression profiles of myogenic factors confirms that a more
effective silencing of Ankrd2 results in a myogenic differentia-
tion capacity of the transfected cells that remains similar to that
of the C2C12 control cells. The strong downregulation of Myh1
in Ankrd2-silenced cells in the late differentiation stages sup-
ports the hypothesis that Ankrd2may have a role in the structural
stability of skeletal muscle [20].
3.4. The Ankrd2 protein level alteration affects myoblast
proliferation
Flow cytometry analysis (FACS) was performed to study the
cell cycle distribution of synchronous cell populations that
overexpress or silence the Ankrd2 protein with respect to con-
trol cells. C2C12 control and transfected clones were plated at
the same density, cultured for 2 days, then harvested and sub-
jected to flow cytometry analysis (n=2). The results in Fig. 3A
show that the overexpression of Ankrd2 promotes cell cycle
arrest proportionally to the overexpression level. The fraction
of cells in S phase decreases from 39% to 27% in the highly
Ankrd2-overexpressing clone compared to control cells. Simul-
taneously the rate of cells in G0/G1 phase increases from 47% to58%. On the other hand, Ankrd2(−)cl.A9 cells with higher level
of Ankrd2-silencing, shows a weak increase of the proliferating
cells fraction that accumulates in the S phase.
It is commonly believed that unbalanced cell cycle progression
occurring in the presence of a contrasting signal for growth arrest
induces apoptosis. Therefore, we examined the expression level
of some genes that are known to play a critical role in initiating
cell cycle arrest in cells that exhibit irregular cellular growth,
namely p53 and three key p53-mediators of apoptosis: cyclin-
dependent kinase inhibitor 1a (Cdkn1a), growth arrest and DNA-
damage-inducible alpha (Gadd45a) and the proapoptotic member
of the Bcl2 family, Bax. Expression levels for Cdkn1a, Gadd45a
andBax are on average 2.1, 2.7 and 1.7 fold higher respectively in
Ankrd2-overexpressing clones compared to the control cells
(Fig. 3B). The level of downregulation of these transcripts mirrors
that of the silenced Ankrd2 gene. The alteration of the Cdkn1a
expression was confirmed also at the protein level (Fig. 3C)
whereas the protein level of p53 remained unchanged, as well as
its mRNA expression level (Fig. 3B and C). In conclusion, the
overexpression of Ankrd2 seems to induce apoptotic cell death in
myoblast cells through the activation of the p53-related pathway
while on the contrary the silencing of Ankrd2 promotes myoblast
proliferation. These results are supported by our microarray data
(Supplementary data, Table S1). For example, Igf2 is strongly
upregulated and downregulated respectively in Ankrd2-over-
expressing and -silencing clones corroborating the findings that
Ankrd2-silencing promotes myoblast proliferation and probably
early myoblast differentiation, while Ankrd2 overexpression
induces cell cycle arrest and apoptosis. In fact IGFs are unique
growth factors, due to their ability to stimulate both proliferation
and differentiation of myoblasts [27].
Finally, since the expression of Cdkn1a, Gadd45a and Bax
are typically mediated by the action of p53 (whose transcript and
protein are found unchanged) we conclude that Ankrd2 modu-
lates the effect of p53 activity on these genes. This observation is
in agreement with previous results showing that Ankrd2 en-
hances the upregulation of the Cdkn1a promoter by p53 [16].
3.5. Alteration of the Ankrd2 protein level modifies cell cycle
regulation
In order to examine how cell cycle regulation is affected by
alterations in Ankrd2 protein level during differentiation we per-
formed BrdU incorporation assays. It is well known that irrever-
sible cell cycle arrest in theG0/G1 phase is an absolute prerequisite
for the induction of differentiation in myoblast cells which is
triggered bymitogen depletion. Both Ankrd2-overexpressing and
-silencing cells were pulse-labelled with 5-bromo2′-deoxy-uri-
dine (BrdU) for 4 h and stained with an anti-BrdU antibody. All
nuclei were made visible by staining with DAPI, and the per-
centage of BrdU-labelled nuclei was determined. The results of
this experiment are shown in Fig. 4A. When the myoblast popu-
lations expressing altered Ankrd2 protein levels were deprived of
serum growth factors we observed a greater fraction of cells that
ceased proliferating and withdrew from the cell cycle in compa-
rison to the C2C12 control culture. The silencing of Ankrd2
seems to promote the early phases of myogenic differentiation, in
Fig. 3. Effect of Ankrd2 alteration on myoblast proliferation and mRNA and protein expression levels of some apoptosis-inducing genes. A. Cell cycle distribution in
proliferating untransfected and transfected myoblasts cultured for 2 days. Myoblasts expressing higher Ankrd2 protein level show a greater fraction of cells that arrest
cell cycle progression. The means±SE of two independent assays for each clones are shown. ⁎Pb0.05%. B. The mRNA level of Cdkn1a, Gadd45a, Bax and p53 for
each transfected clone is expressed as fold increase relative to control cells. Data are the mean±SE of three values. ⁎Pb0.05%. C. Western blot of protein extracts from
untransfected (C1), empty vector-transfected control cells (C2) and Ankrd2 transfected clones with anti-Cdkn1a and anti-p53 antibodies; Hdac1 is the loading control.
Overall, the overexpression of Ankrd2 promotes upregulation of key p53-mediators of apoptosis.
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the high rate of cell cycle exit in the Ankrd2-overexpressing
clones could be due to enrichment in quiescent cells (MyoD- and
Myf5+) as a result of the high rate of apoptotic cell death ofmyoblasts that are unable to differentiate. In fact we have shown
that both MyoD and Myogenin were downregulated and that
Myf-5 was upregulated in Ankrd2-overexpressing clones rela-
tive to the C2C12 control cells (Fig. 2C) and that the intracellular
Fig. 4. Effects of Ankrd2 alteration on cell cycle regulation, apoptosis and cell viability. A. The percentage of proliferating cells was evaluated by the BrdU
incorporation assay in myoblasts growing or after 1, 3 and 6 days from induction of differentiation. After 1 day, in myocytes expressing altered levels of Ankrd2
protein, a greater fraction of cells ceased proliferating and withdrew from the cell cycle. B. Among the myoblast population induced for 1 day the percentage of
apoptotic cells was quantified by counting cells with activated caspases (FLICA assay). Both Ankrd2 overexpression and silencing increase the rate of apoptotic cells
compared to C2C12 control cells. C. Growing and 1, 3, 6 day differentiation induced myoblasts were assayed for caspase-3 activity using the fluorescent substrate
DEVD-pNA as described in the Materials and methods. The Ankrd2-silencing myoblasts have higher caspase 3 activity but after induction of myogenesis the trend
recapitulates that of control myotubes. On the contrary, in Ankrd2-overexpressing myotubes the caspase 3 activity was higher than control cells in the later
differentiation stages. D. Cell viability was determined by the MTT assay in myoblasts without or with 1, 3 and 6 days of growth in differentiation medium. Ankrd2-
overexpressing and -silencing cells are respectively less and more viable than control cells. In every assay the error bars represent the 95% confident intervals.
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estimated changes in the total number of cells during differentia-
tion and show that, after induction of myogenic differentiation,
the total number of cells decreased in Ankrd2-overexpressing
clones supporting the hypothesis of cell death (Supplementary
data, Fig. S1).
3.6. Ankrd2 alteration modifies the potential of myoblasts to
acquire the apoptosis-resistance phenotype upon differentiation
To confirm the induction of apoptotic pathways by Ankrd2
overexpression we have measured the activity of caspases that
are the primary regulators of programmed cell death. We used an
approach based on fluorochrome inhibitors of caspases (FLICA)
which covalently bind to the active caspases inside the cells. The
percentage of rhodamine fluorescent cells was measured in the
transfected C2C12 cell clones. The results, reported in Fig. 4B,
show that both Ankrd2 overexpression and silencing increase
the percentage of apoptotic cells up to about 10 times with
respect to C2C12 control cells 1 day after induction of myogenic
differentiation. These results confirm that Ankrd2 plays a role
in regulating cell proliferation and cell survival. To understandthe meaning of the higher rate of caspase activity in Ankrd2-
silencing cells vs. control cells, we assayed caspase 3 activity
that is associated with skeletal muscle differentiation and which
is not strictly apoptotic [28]. In fact, peptide inhibition of caspase
3 activity or homologous deletion of the caspase 3 gene led to a
reduction of myotube/myofibre formation and the expression of
muscle-specific proteins. These results indicate that signalling
mediated by caspase 3, in addition to its apoptotic role, is
required for skeletal muscle differentiation. The activity of cas-
pase 3 in C2C12 control cells during myogenic differentiation
reflects previous data showing a peak of caspase 3 activity 1 day
after the induction of myogenic differentiation [28]. The acti-
vation of caspase 3 during myogenesis might be required for the
ablation of differentiation-incompetent myoblasts and the in-
duction of the myogenic program in myoblasts. In Fig. 4C we
show that the Ankrd2-silencing myoblasts have higher caspase 3
activity than control cells, while after induction of myogenesis
the activity is similar to control myotubes. We have previously
observed that Ankrd2-silencing in proliferating myoblasts in-
duced to differentiate enhances cell cycle arrest likely promoting
the differentiation. In these clones the caspase 3 activity might
be increased to sustain myogenic differentiation by removal of
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Ankrd2-overexpressing myotubes caspase 3 activity remains
higher than control cells in later differentiation stages. We con-
clude that in the overexpressing clones the activity of caspase 3
might be strictly apoptotic.
3.7. Alteration of the Ankrd2 expression changes cell viability
Finally, we assessed cell viability during myogenic differ-
entiation based on mitochondrial function, by determining the
ability of cells to convert soluble 3-(4,5-dimethylthiazol-2-yl)-2-
5-diphenyltetrazolium bromide (MTT) into the insoluble purple
formazan reaction product (Fig. 4D). Percentage of cell viability
indicates rates of mitochondrial respiration or activity of mito-
chondrial dehydrogenases. We found that Ankrd2-overexpres-
sing cells are less viable than control cells, in agreement with
previous results showing the induction of cell death. The viabi-
lity among the Ankrd2-silencing cell population was higher than
that in the C2C12 control cells, in agreement with the results
showing that the silencing of Ankrd2 promotes exit from cell
cycle and the acquisition of an apoptosis-resistance phenotype,
as shown in the experiments discussed above.
3.8. Analysis of transcriptional alterations induced by Ankrd2
overexpression and silencing
The experiments we carried out to characterize Ankrd2-
overexpressing and -silencing C2C12 clones suggest that Ankrd2
modifies the ability of muscle cells to undergo differentiation by
altering the regulation of the cell cycle. It is known that Ankrd2 is
able to regulate the expression of specific target genes acting as
transcriptional co-factor [16]. To identify Ankrd2-partner genes
involved in the regulation of the crucial steps of the myogenic
program we performed a series of DNA microarray experiments
to determine the transcriptional profile alterations of Ankrd2-
overexpressing and -silencing cells. This transcriptome analysis
was restricted to the myoblast stage since the nuclear localization
of the Ankrd2 protein occurs at that stage.
RNA purified from each C2C12 clone was compared with
RNA fromC2C12 control cells. These samples were labelled and
hybridized to the Mouse Oligonucleotide Microarray Platform
consisting of 13,443 70mer oligonucleotides (Operon) spotted
in two replicates (http://microcribi.cribi.unipd.it/e-index.htm;
GEO database, accession number GPL5098). For each clone,
two separate experiments were performed with RNA samples
labelled alternatively with Cy3 or Cy5 fluorochromes. All mic-
roarray data were normalized with the MIDAW tool [25] and the
normalized datasets were deposited in the NCBIs Gene Expres-
sion Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number GSE7542. The
replicates of each experiment were separated and the resulting 16
expression datasets were analysed by the Significance Analysis
of Microarray (SAM) used as a statistical test for the identi-
fication of differentially expressed genes. We performed two
independent one-class SAM analyses with each of the 8 datasets
corresponding to the Ankrd2-overexpressing and -silencing mic-
roarray experiments. Moreover, a two-class analysis was doneusing all of the 16 datasets taken together. The false discovery
rate (FDR) was set at the value 0.58% in SAM two-class analysis
and 0.96% and 0.73% respectively in Ankrd2-overexpressing
and -silencing one-class analysis. The differentially expressed
genes belonging to specific functional categories that are relevant
to define the role of Ankrd2 in myogenic differentiation are listed
in three tables that can be found in the Supplementary data. Here
we have reported a list of differentially expressed genes which are
known p53-target genes or are co-activators for p53 activity in
inducing extensive apoptosis and G1 arrest (Table 1). Indeed, as
previously discussed, we have attributed the alteration of cell
cycle regulation in Ankrd2-overexpressing and -silencing cells to
the ability of Ankrd2 to modulate p53-transcriptional activity.
In fact we have found up- and downregulated respectively in
Ankrd2-overexpressing and -silencing clones both the mRNA
and the protein produced by the Cdkn1a gene that is known to be
activated by the Ankrd2-enhancement of p53 activity [16].
Overall, Ankrd2mightmodulate gene expression both enhancing
and silencing the transcriptional activity of p53. Our data provide
a list of candidate genes, whose expression might be affected by
Ankrd2. For example, Pml, Gas, Peg3, Trp53inp1 are known
downstream effectors of p53 or direct p53-target genes that
induce cell cycle arrest [29–32] and are also found considerably
altered in our SAM analysis. Furthermore, Pml, a tumour growth
suppressor that regulates cell cycle progression and interacts with
Ankrd2 in the nuclear bodies (NBs), is differentially expressed.
Pml NBs are macromolecular nuclear domains where transcrip-
tional factors (i.e. p53) and co-factors (i.e. Ankrd2) associate to
regulate gene expression [33]. We think that the Pml transcrip-
tional deregulation could be one of the most important factors
contributing to the alterations of the myogenic differentiation in
the Ankrd2-overexpressing and -silencing clones.
Also listed in the Supplementary data are the genes showing an
altered expression profile in the C2C12 clones, these belong to the
functional classes of skeletalmuscle development and contraction
(Supplementary data, Table S2). Avery interesting result is given
by the strong downregulation in the Ankrd2-overexpressing
clones of both regulatory (MyoD and Myogenin) and structural
(Myh3, Myh7, Tnni2, etc) muscle-specific genes. These data are
in agreement with the results obtained by real-time-PCR
experiments (Fig. 2C) showing a strong inhibition of myogenic
differentiation in the Ankrd2-overexpressing cells. Two Western
blot experiments (Supplementary data, Fig. S2) show that the
level of myosin proteins mirrors these expression data.
Moreover these results are in agreement with the findings that
the overexpression of CARP, the cardiac homologue of Ankrd2,
results in the inhibition of cardiac genes [17,34]. In fact, CARP
binds to andmay act as a co-factor of the ubiquitous transcription
factor YB-1, that can function as a negative regulator of ventri-
cular specific HF-1a-dependent myosin light chain-2 (MLC-2v)
transcription during cardiogenesis.
Finally, we have listed (Supplementary data, Table S3) the
significantly altered transcripts that can be classified in the
functional classes of cell adhesion and cytoskeletal organization.
All cellular events taking place during myogenic differentiation
require the integrity as well as the regulated remodelling of the
extracellular matrix (ECM). Our microarray results show that
Table 1
Differentially expressed genes identified by oligonucleotide microarray (partial list)
Gene name Oligo_ID Plate_ID Gene_ID Ankrd2(−) clones Ankrd2(+) clones
Cell cycle and apoptosis
Ccng2: cyclin G2 M001258_01 004A20 12452 4.09±0.25⁎ −2.42±1.12⁎
Plagl1: pleiomorphic adenoma gene-like 1 M005082_01 014O11 22634 2.41±0.51⁎ −3.72±0.23⁎
Peg3: paternally expressed 3 M002396_01 007O15 18616 2.00±0.74 −3.23±0.39⁎
Trp53inp1: transformation related protein 53 inducible nuclear protein 1 M004243_01 012C13 60599 2.09±0.49 −1.56±0.38
Pml: promyelocytic leukaemia M004821_01 013D18 18854 1.45±0.41 −1.41±0.36
Gas1: growth arrest specific 1 M003738_01 010P12 14451 3.97±0.66⁎ 0.44±0.55
Cgrrf1: cell growth regulator with ring finger domain 1 M011991_01 032 E22 68755 0.91±0.30 −1.73±0.48
Glipr1: GLI pathogenesis-related 1 (glioma) M013009_01 034P17 73690 −1.99±0.71 1.70±0.48
Myc: myelocytomatosis oncogene alias c-Myc M000834_01 003K11 17869 −2.37±0.62⁎ 0.93±0.52
Syvn1: synovial apoptosis inhibitor 1, synoviolin M007790_01 021I20 74126 4.31±1.05
Bnip3: BCL2/adenovirus E1B interacting protein 1, NIP3 M000742_01 002L19 12176 1.57±0.25
Cdk7: cyclin-dependent kinase 7 M003552_01 010O23 12572 −1.88±0.31
Cdc7: cell division cycle 7 (S. cerevisiae) M003457_01 010A01 12545 −2.24±0.48
Muscle contraction and muscle development
Tcf4: transcription factor 4 M001517_01 004N09 21413 3.00±0.34⁎ −1.20±0.29
Sema5a: semaphorin 5A M003878_01 011G03 20356 3.46±0.47⁎ −1.48±0.71
Cxcl12 : chemokine (C-X-C motif) ligand 12 M000143_01 001G22 20315 1.76±0.55 −1.28±0.22
Zfhx1a: zinc finger homeobox 1a M001372_01 004F08 21417 1.63±0.24⁎ −0.12±0.11
Cell adhesion and cytoskeletal organization
Spp1: secreted phosphoprotein 1 M000097_01 001A02 20750 3.63±0.76⁎ −1.77±0.42 ⁎
List of genes with altered expression profiles in Ankrd2-overexpressing and -silencing C2C12 clones that are known p53-target genes or that are co-activators for p53
activity regulated cell cycle and apoptosis. Each expression value represents the mean of 8 log2 ratio±SD of technical replicates, ⁎ identifies genes being significant in
both two-class and one-class SAM analyses. GenBank Gene name and ID (Gene_ID) is used to identify each gene. Oligo_ID and Plate_ID refer to the identity of
70mer oligonucleotide probe and position of the probe in the mouse microarray platform, respectively.
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migration are differentially expressed in Ankrd2-overexpressing
and -silencing clones.
In particular, the microarray data suggest that the Ankrd2-
silencing could promote myoblast fusion through the upregula-
tion of genes positively regulating the fibre formation. For ex-
ample, Spp1, a p53-target gene [35] is found upregulated in
Ankrd2-silencing and downregulated in Ankrd2-overexpressing
clones. This gene is thought to be important mainly during the
early stages of myogenesis by facilitating myoblast fusion and
differentiation [36]. On the contrary, Ankrd2-overexpressing
cells upregulate genes known to be robustly overexpressed dur-
ing the muscle repair process.
In summary, the microarray results support our findings
about the role of the Ankrd2 protein in myogenic differentiation
and identify many putative Ankrd2-regulated genes that can
clarify the role of this protein in muscle cell differentiation.
4. Discussion
Skeletal muscle Ankrd2 has been the focus of many studies
[13–15,4,10,20,37], but its role in myogenic differentiation has
been largely ignored. We have shown that in proliferating myo-
blasts Ankrd2 is restricted to the nucleus, but as the myoblasts
differentiate into multinucleated myotubes Ankrd2 protein accu-
mulates in the cytoplasm. This nuclear localization suggested to
us a possible role for Ankrd2 as myogenic regulator. Our hypo-
thesis was supported by previous data showing that Ankrd2 can
not only bind specific transcription factors but also modulatetheir transcriptional activity [16], similar to its homologue
CARP [17,34]. To understand the role of Ankrd2 in muscle
differentiation our strategy was to alter the Ankrd2 protein level
(overexpression or silencing) in the model cell line C2C12,
because of its recognized capacity to recapitulate the muscle
differentiation program. Myogenic differentiation involves a
hierarchical series of events in which the muscle precursor cells
(myoblasts) irreversibly exit the cell cycle, acquire an apoptosis-
resistance phenotype, upregulate the expression of muscle-spe-
cific proteins and finally fuse to form terminally differentiated
multinucleated cells (myotubes) [38]. Thus, myogenic differen-
tiation is accompanied by dramatic changes in cell morphology
and cell architecture in response to the necessity of the reor-
ganization of cytoskeletal proteins to form the functional sar-
comere. We analyzed the most crucial aspects of myogenic
differentiation by comparing stable Ankrd2-overexpressing and
-silencing C2C12 clones with C2C12 control cells. The differ-
entiation of myoblasts induced by mitogen depletion leads to i) a
subpopulation of cells undergoing terminal differentiation and
fusing into myotubes, ii) a subpopulation called “reserve cells”
that remain undifferentiated and share many characteristics with
muscle satellite cells [39] and iii) a subset of cells undergoing
apoptosis [40]. Our results show that the percentage of these
subpopulations is altered in the Ankrd2-transfected clones with
respect to that of the control cells. The morphological charac-
terization highlights that Ankrd2 overexpression dramatically
affects myogenic differentiation. Most remarkably, in Ankrd2-
overexpressing clones the greater impairment of myogenic differ-
entiation is associated with a correspondent large downregulation
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Myogenin and their target Myh1, a terminal differentiation
marker. These data were confirmed by both real-time-PCR and
microarray experiments. The upregulation of Myf-5, which is
normally absent from all differentiating cells [26] supports the
previous findings concerning the failure of myogenic differ-
entiation. Moreover, the reduced protein expression level of
myosins confirms the impairment of the differentiation process
by Ankrd2 overexpression. We investigated the regulation of
the cell cycle in order to elucidate the mechanisms by which
Ankrd2 alters myogenic differentiation. All data obtained
indicate that the overexpression of Ankrd2 alters cell cycle
regulation and induces apoptosis. In fact, myoblasts that ex-
press high levels of Ankrd2 protein cease proliferation, show
cell cycle arrest and activate the p53-apoptotic pathway, as
seen by the upregulation of the most important p53-mediators
of apoptosis Cdkn1a, Gadd45a and Bax. Since it is known that
Ankrd2 modulates p53 activity enhancing the expression of its
target Cdkn1a [16], we conclude that the impairment of myo-
genic differentiation by Ankrd2 might be due to its role as
p53-transcriptional co-factor. On the other hand, we show that
the Ankrd2-silencing myoblasts actively proliferate and do not
undergo apoptosis, and this is reflected by the downregulation
of Cdkn1a, Gadd45a and Bax, upregulated in Ankrd2-over-
expessing clones. Moreover, the silencing of Ankrd2 promotes
cell cycle exit of myoblasts induced to differentiate probably
favouring the initial stage of myogenic differentiation. This
hypothesis is supported both by the higher caspase 3 activity
and by the higher fraction of cell viability measured in Ankrd2-
silencing myocytes compared to C2C12 control cells. On the
contrary, in the late stages of differentiation, the morphological
analysis and the assessment of the fusion indexes in the silenced
clones indicate a weak reduction of the myogenic potential
which is inversely correlated with the extent of Ankrd2-silenc-
ing, for example, the greater the silencing the lower the reduc-
tion in myogenic potential. This is not surprising, since the
investigations into the skeletal muscle phenotype of mice lack-
ing the genes of the MARP family did not show defects in
muscle development [20]. We conclude that in the proliferating
stage of myoblasts Ankrd2 might control myocyte differentia-
tion coordinating proliferation and apoptosis whereas in the
differentiated stages it might stabilize the forming myotubes
protecting them against mechanical stress. The role of Ankrd2
in the apoptotic pathway is not surprising since it has been seen
that the ectopic expression of the ANKRD1/CARP protein
(which shows a high level of structural and functional conser-
vation with Ankrd2) led to reduced colony formation and to
enhanced apoptotic cell death in hepatoma cells. [41]. More-
over, it was suggested that ANKRD1/CARP induction may at
least in part play a role in GADD153-mediated sensitization of
apoptotic cell death [42].
We used a genomic approach based on microarray techno-
logy in order to identify the gene networks that are disturbed by
Ankrd2 overexpression and silencing. We performed the expe-
riments at the myoblast stage, because at that stage Ankrd2
localizes in the nucleus where it may act as a myogenic tran-
scriptional regulator. The stable alteration of Ankrd2-expressionlevel resulted in the modulation of different muscle differentia-
tion-related genes belonging to functional classes that have key
roles in myogenesis (cell cycle regulation and apoptosis; ske-
letal muscle development and contraction; cell adhesion and
cytoskeletal organization). In this context, it is interesting to
note that the transcriptional profile of Ankrd2-overexpressing
clones highlights a remarkable impairment of the myogenic
differentiation program. In particular, both early (i.e. MyoD and
Myogenin) and late (i.e. several myosin and troponin isoforms)
differentiation markers are downregulated compared to C2C12
control cells, as confirmed by real-time-PCR and Western blot
experiments. Moreover, these results are in agreement with the
ability of Ankrd1/CARP to act as a negative transcriptional co-
regulator of cardiac-specific genes [17,34]. On the other hand,
in Ankrd2-silencing clones numerous genes that regulate the
cell cycle and that might promote the induction of differentia-
tion are differentially expressed. For example, c-Myc is found
downregulated. The downregulation of c-Myc is considered an
important event in the induction of differentiation in numerous
cell lines including murine and avian myoblasts [43,44]. More-
over, it was recently demonstrated that c-Myc expression is
negatively regulated by mitochondrial activity suggesting that
c-Myc is a primary target of mitochondrial activity involved in
the regulation of myoblast differentiation [45]. This is in agree-
ment with our results showing that Ankrd2-silencing clones
have higher rates of mitochondrial respiration compared to
control cells. In addition, the upregulation of Igf-2 corroborates
our conclusions. It is known that IGF-2 acts as an autocrine
survival factor for myoblasts during the transition from prolife-
rating to differentiating cells by preventing inappropriate cell
death [46]. Conversely, Igf-2 is downregulated in Ankrd2-
overexpressing clones undergoing apoptosis.
It is interesting to note that many differentially expressed
genes revealed by microarray experiments are known p53-target
genes or p53-downstream effectors. The effect of p53 in myo-
genic differentiation is likely to be very intricate, involving
many different effectors. Each p53-transcriptional target is asso-
ciated to its own modulator that may influence muscle dif-
ferentiation. Here, we present the first evidences that Ankrd2
protein may influence myogenic differentiation by modulating
p53 activity. In addition, our analysis of the perturbed pathways
identifies novel putative Ankrd2-modulated genes.
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